Literature DB >> 31821791

Clinical significance of urinary plasminogen and fibrinogen gamma chain as novel potential diagnostic markers for non-small-cell lung cancer.

Wencheng Zhang1, Zhouyong Gao2, Guang Zeng3, Hui Xie4, Jinbo Liu5, Ning Liu6, Guangshun Wang7.   

Abstract

BACKGROUND: Urinary proteins could be useful as markers for the detection of non-small-cell lung cancer (NSCLC). We investigated the levels of two different proteins in urine samples from NSCLC patients and assessed their diagnostic value.
METHODS: Urinary plasminogen (PLG) and fibrinogen gamma chain (FGG) levels in 112 NSCLC patients and 197 controls were detected using enzyme linked immunosorbent assay (ELISA). The expression of FGG and PLG in 20 NSCLC tissues and paired adjacent non-tumour tissues were detected through immunohistochemistry. The diagnostic value of FGG and PLG for NSCLC was evaluated through a receiver operating characteristic curve (ROC).
RESULTS: PLG and FGG were significantly elevated in NSCLC tissues vs paired adjacent non-tumour tissues (p = 0.000) and in urinary samples from NSCLC patients vs healthy controls (p = 0.000). The expression level of PLG in urinary samples was related only to the histological type (p = 0.001). Further, ROC curve analysis revealed that PLG, FGG, and their combination could distinguish NSCLC and its subtypes from healthy controls with an AUC ranging from 0.827 to 0. 947. By comparing urine samples with matching plasma CEA from NSCLC stage I-IV patients (n = 81) and healthy controls (n = 31), the combination of CEA with PLG or FGG showed that the AUC was 0.889 and 0.806, respectively, which is superior to a single biomarker alone.
CONCLUSIONS: These two urinary proteins could serve as potential markers for the diagnosis of NSCLC.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diagnostic marker; Fibrinogen gamma; Non-small-cell lung cancer; Plasminogen; Urine

Year:  2019        PMID: 31821791     DOI: 10.1016/j.cca.2019.11.022

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Urinary protein biomarker panel predicts esophageal squamous carcinoma from control cases and other tumors.

Authors:  Linlin Ji; Jianping Wang; Bo Yang; Jianping Zhu; Yini Wang; Jiaqi Jiao; Kai Zhu; Min Zhang; Liqiang Zhai; Tongqing Gong; Changqing Sun; Jun Qin; Guangshun Wang
Journal:  Esophagus       Date:  2022-07-06       Impact factor: 3.671

2.  [Identification of Candidate Biomarkers for EGFR-T790M Drug-resistant 
Gene Mutation in Advanced Lung Adenocarcinoma].

Authors:  Lijuan Chen; Li Shan; Tingting Yu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-11-20

3.  Identification of potential core genes in colorectal carcinoma and key genes in colorectal cancer liver metastasis using bioinformatics analysis.

Authors:  Lipeng Niu; Ce Gao; Yang Li
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

4.  Proteomic Exploration of Plasma Exosomes and Other Small Extracellular Vesicles in Pediatric Hodgkin Lymphoma: A Potential Source of Biomarkers for Relapse Occurrence.

Authors:  Ombretta Repetto; Federica Lovisa; Caterina Elia; Daniel Enderle; Filippo Romanato; Salvatore Buffardi; Alessandra Sala; Marta Pillon; Agostino Steffan; Roberta Burnelli; Lara Mussolin; Maurizio Mascarin; Valli De Re
Journal:  Diagnostics (Basel)       Date:  2021-05-21

5.  A Quest for New Cancer Diagnosis, Prognosis and Prediction Biomarkers and Their Use in Biosensors Development.

Authors:  Eda G Ramirez-Valles; Alicia Rodríguez-Pulido; Marcelo Barraza-Salas; Isaac Martínez-Velis; Iván Meneses-Morales; Víctor M Ayala-García; Carlos A Alba-Fierro
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.